Although it rarely arises de novo, NEPC may emerge from prostate adenocarcinoma (adeno-PCa) due to lineage plasticity induced by androgen receptor (AR)-targeted therapy1,2. The gene discussed is AR; the disease is prostate adenocarcinoma.